Hye Young Lee

Hye Young Lee

Auto-generated profile, based on publicly available information

Hye Young Lee

Division of Infectious Disease Response, Chungcheong Regional Center for Disease Control and Prevention, Korea Disease Control and Prevention Agency, Daejeon, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJi Joo Lee
Ji Joo Lee
YCYoung June Choe
Young June Choe
HJHyeongseop Jeong
Hyeongseop Jeong
MKMoonsu Kim
Moonsu Kim
SKSeonggon Kim
Seonggon Kim
YPYoung-Joon Park
Young-Joon Park
Lee JJ, et al. J Korean Med Sci. 2021 Dec;36(50):e346. https://doi.org/10.3346/jkms.2021.36.e346

31 December 2022 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
HPHanul Park
Hanul Park
YPYoung-Joon Park
Young-Joon Park
HLHye Young Lee
Hye Young Lee
MYMi Yu
Mi Yu
YSYeong-Jun Song
Yeong-Jun Song
YKYeonjung Kim
Yeonjung Kim
Objectives: On November 5, 2021, Pfizer Inc. announced Paxlovid (nirmatrelvir+ritonavir) as a treatment method that could reduce the risk of hospitalization or death for patients with confirmed coronavirus disease 2019 (COVID-19).Methods: From February 6, 2022 to April 2, 2022, the incidence of COVID-19 and the effects of treatment with Paxlovid were analyzed in 2,241 patients and workers at 5 long-term care facilities during the outbreak of the Omicron variant of severe acute respiratory syndrome coronavirus 2 in South Korea.Results: The rate of severe illness or death in the group given Paxlovid was 51% lower than that of the non-Paxlovid group (adjusted risk ratio [aRR], 0.49; 95% confidence interval [CI], 0.24−0.98). Compared to unvaccinated patients, patients who had completed 3 doses of the vaccine had a 71% reduced rate of severe illness or death (aRR, 0.29; 95% CI, 0.13−0.64) and a 65% reduced death rate (aRR, 0.35; 95% CI, 0.15−0.79).Conclusion: Patients given Paxlovid showed a lower rate of severe illness or death and a lower fatality rate than those who did not receive Paxlovid. Patients who received 3 doses of the vaccine had a lower rate of severe illness or death and a lower fatality rate than the unvaccinated group.

13 September 2022 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
MSMinjoung Shin
Minjoung Shin
JKJa Eun Kim
Ja Eun Kim
HLHye Young Lee
Hye Young Lee
SLSu-Yeon Lee
Su-Yeon Lee
SLSang Eun Lee
Sang Eun Lee
HLHyungmin Lee
Hyungmin Lee
Shin M, et al. J Korean Med Sci. 2022 Sep;37(37):e285. https://doi.org/10.3346/jkms.2022.37.e285

30 June 2024 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
HLHye Young Lee
Hye Young Lee
YKYunhyung Kwon
Yunhyung Kwon
SLSang Eun Lee
Sang Eun Lee
JKJieun Kim
Jieun Kim
HCHoyong Choi
Hoyong Choi
Objectives: Between July 2, 2021, and September 20, 2022, a Mycobacterium bovis outbreak occurred among exhibition animals at a zoo in the Republic of Korea. This study was conducted to assess the likelihood of M. bovis transmission to human contacts through a contact investigation and to implement preventive treatment for latent tuberculosis infection (LTBI).Methods: In this descriptive study, the Korea Disease Control and Prevention Agency conducted a contact investigation, which included interviews, interferon-gamma release assay (IGRA) tests, and chest X-rays. Contacts underwent IGRA testing on 2 occasions: initial testing of 29 contacts (15 in the first cluster of infection and 14 in the second cluster) and follow-up testing of the 15 contacts in the first cluster.Results: The study included 29 participants, 18 of whom were male (62.1%) and 11 female (37.9%). The mean participant age was 37.3 years (standard deviation, 9.6 years). In the initial IGRA tests, 6 of the 29 participants tested positive, indicating a prevalence of 20.7%. Following prolonged exposure, 1 additional positive case was detected in follow-up testing, raising the prevalence of LTBI to 24.1%. None of the contacts had active tuberculosis. Among the 7 individuals with positive results, 2 (28.6%) underwent treatment for LTBI.Conclusion: This study faced challenges in confirming the transmission of M. bovis infection from infected animals to humans in the Republic of Korea. Nevertheless, adopting a One Health approach necessitates the implementation of surveillance systems and infection control protocols, particularly for occupational groups at high risk of exposure.

1 January 2023 in Infection & Chemotherapy
Verified
Journal Article
Open access
HLHye Young Lee
Hye Young Lee
YPYoung-Joon Park
Young-Joon Park
MYMi Yu
Mi Yu
HPHanul Park
Hanul Park
JLJi Joo Lee
Ji Joo Lee
SLSang Eun Lee
Sang Eun Lee
Lee HY, et al. Infect Chemother. 2023 Sep;55:e41. https://doi.org/10.3947/ic.2023.0059

30 June 2023 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
MYMi Yu
Mi Yu
SLSang Eun Lee
Sang Eun Lee
HLHye Young Lee
Hye Young Lee
HKHye-Jin Kim
Hye-Jin Kim
YSYeong-Jun Song
Yeong-Jun Song
YPYoung-Joon Park
Young-Joon Park
Objectives: This study aimed to assess the contact tracing outcomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-lineages BA.4, BA.5, and BA.2.75 within Republic of Korea, and to generate foundational data for responding to future novel variants.Methods: We conducted investigations and contact tracing for 79 confirmed BA.4 cases, 396 confirmed BA.5 cases, and 152 confirmed BA.2.75 cases. These cases were identified through random sampling of both domestically confirmed and imported cases, with the goal of evaluating the pattern of occurrence and transmissibility.Results: We detected 79 instances of Omicron sub-lineage BA.4 across a span of 46 days, 396 instances of Omicron sub-lineage BA.5 in 46 days, and 152 instances of Omicron sub-lineage BA.2.75 over 62 days. One patient with severe illness was confirmed among the BA.5 cases; however, there were no reports of severe illness in the confirmed BA.4 and BA.2.75 cases. The secondary attack risk among household contacts were 19.6% for BA.4, 27.8% for BA.5, and 24.3% for BA.2.75. No statistically significant difference was found between the Omicron sub-lineages.Conclusion: BA.2.75 did not demonstrate a higher tendency for transmissibility, disease severity, or secondary attack risk within households when compared to BA.4 and BA.5. We will continue to monitor major SARS-CoV-2 variants, and we plan to enhance the disease control and response systems.